Background: Ghrelin is a newly recognized gastric hormone with orexigenic and adipogenic properties, produced primarily by the stomach. Ghrelin is reduced in obesity. Weight loss is associated with an increase in fasting plasma ghrelin. We assessed the effect of massive weight loss on plasma ghrelin concentrations and its correlation with serum leptin levels and the presence of type 2 diabetes mellitus (DM) in severely obese patients.
Methods: A prospective study was conducted on 28 morbidly obese women (BMI 56.3 +/- 10.2 kg/m2) who underwent gastric bypass, divided into 2 groups: 14 non-diabetics (NGT) and 14 type 2 diabetics (DM2). Ghrelin and leptin were evaluated before silastic ring transected vertical gastric bypass, and again 12 months postoperatively.
Results: Fasting plasma ghrelin concentrations were 56% lower in NGT and 59% lower in DM2 compared with a lean control group (P < 0.001). There was no difference in ghrelin levels between NGT and DM2 groups before and after surgery (P > 0.05). Ghrelin was negatively correlated with leptin before gastric bypass surgery (r = 0.51, P < 0.01). The mean plasma ghrelin concentration decreased significantly after surgery in both groups (P < 0.001).
Conclusion: Ghrelin was inversely related to leptin concentrations. Presence of diabetes did not affect the ghrelin pattern. Reduced production of ghrelin after gastric bypass could be partly responsible for the lack of hyperphagia and thus for the weight loss.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1381/096089203321136539 | DOI Listing |
Dig Dis Sci
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, West Virginia University, 5th Floor Health Sciences Center, Suite 5500, PO Box 9161, Morgantown, WV, 26506, USA.
Langenbecks Arch Surg
January 2025
Department of Visceral, Transplant, Thoracic and Vascular Surgery, Leipzig University Hospital, Leipzig, Germany.
Purpose: Obesity and type 2 diabetes (T2DM) are major risk factors for hepatic steatosis. Diet or bariatric surgery can reduce liver volume, fat content, and inflammation. However, little is known about their effects on liver function, as evaluated here using the LiMAx test.
View Article and Find Full Text PDFCureus
December 2024
Trauma and Acute Care Surgery, Northeast Georgia Medical Center Gainesville, Gainesville, USA.
Roux-en-Y gastric bypass (RYGB) is a common surgical treatment for morbid obesity, but rare complications involving the excluded gastric remnant can pose significant challenges. A 65-year-old female with a history of RYGB presented with sudden onset of left upper quadrant abdominal pain, bloating, nausea, and loss of appetite. Laboratory tests revealed leukocytosis.
View Article and Find Full Text PDFJ Metab Bariatr Surg
December 2024
Integrated Responsibility Center for Obesity (CRI-O), São João Local Health Unit (ULS), Porto, Portugal.
Purpose: Metabolic and bariatric surgery (MBS) is an effective treatment for patients with body mass index (BMI) above 50.0 kg/m but nutritional deficiencies (ND) may arise. This study aimed to assess if patients with BMI above 50.
View Article and Find Full Text PDFJ Diabetes Metab Disord
June 2025
Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College, Lyari, Karachi, Pakistan.
Background: The growing incidence of obesity has led to a proportionate rise in type 2 diabetes mellitus (T2DM) and its associated complications. We aimed to compare the long-term outcomes of Roux-en-y Gastric Bypass surgery (RYGB) and conventional medical management in T2DM obese patients.
Methods: PubMed, Google Scholar, and Clinicaltrial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!